Newer Targeted Agents in NSCLC: ALK Inhibitors

Alice Shaw highlights the development and clinical considerations for use of first- and next-generation ALK inhibitors in NSCLC, plus ongoing research.

Source: CancerNetwork - June 14, 2018 Category: Cancer & Oncology Authors: Alice T. Shaw, MD, PhD Source Type: news